Deletions of the long arm of chromosome 11 (11q) have been noted in primary neuroblastomas, but a comprehensive analysis has not been performed. Therefore, we analysed 331 neuroblastomas (295 sporadic, 15 familial and 21 tumor-derived cell lines) to determine the prevalence of 11q allelic deletions, to map the location of a putative tumor suppressor gene and to perform clinical correlative studies. Assays for loss of heterozygosity (LOH) were performed at 24 microsatellite loci spanning 11q. LOH was observed at multiple 11q loci in 129/295 (44%) sporadic neuroblastomas, 5/15 (33%) familial neuroblastomas, and 5/21 (24%) neuroblastoma cell lines. A single region of 2.1 cM within 11q23.3, anked by markers D11S1340 and D11S1299, was deleted in all specimens with 11q LOH. Allelic loss at 11q23 was inversely related to MYCN ampli®cation (P50.001). Within the subset of cases with a single copy of MYCN, 11q LOH was associated with advanced stage disease (P=0.008), unfavorable histopathology (P=0.042), and decreased overall survival probability (P=0.008). However, 11q LOH was not independently prognostic in multivariate analyses. These data support the hypothesis that a tumor suppressor gene mapping within 11q23.3 is commonly inactivated during the malignant evolution of a large subset of neuroblastomas, especially those with unampli®ed MYCN.
Introduction
Neuroblastoma is a common pediatric neoplasm that demonstrates striking clinical heterogeneity. Genetic alterations help explain this diversity and de®ne distinct subsets of patients . Neuroblastomas with ampli®cation of the MYCN proto-oncogene are typically diagnosed in patients over one year of age, are highly malignant and de®ne a patient population with a poor survival probability despite intensive, multimodal therapy. The majority of these tumors have a diploid or tetraploid DNA content and other chromosomal rearrangements such as deletion of the short arm of chromosome 1. In contrast, neuroblastomas identi®ed during infancy usually have a hyperdiploid DNA content, few (if any) chromosomal rearrangements, and are usually cured with surgery alone. However, a signi®cant number of neuroblastoma patients have an intermediate clinical phenotype and the genetic alterations present in this group of tumors are not well de®ned.
Cytogenetic and molecular genetic studies have led to the hypothesis that neuroblastoma tumorigenesis relies upon inactivation of several tumor suppressor genes. Deletions of chromosome band 1p36 have been well characterized, occur in approximately 30 ± 35% of primary tumors and are highly correlated with ampli®cation of MYCN (Caron et al., 1996b; Gehring et al., 1995; Maris et al., 1995; Martinsson et al., 1995; White et al., 1995) . However, nonrandom deletions of chromosomal regions other than 1p36 have been noted in neuroblastomas, suggesting additional neuroblastoma suppressor genes may be involved in tumorigenesis, especially in the subset of tumors with normal 1p36 and MYCN.
Several lines of evidence indicate that the long arm of chromosome 11 (11q) contains a neuroblastoma suppressor gene. Deletions of 11q have been noted in approximately 15 ± 20% of reported neuroblastoma karyotypes (Mertens et al., 1997) , and transfer of an intact chromosome 11 into the neuroblastoma cell line NGP induced dierentiation (Bader et al., 1991) . Constitutional rearrangements of 11q have also been observed in some neuroblastoma patients (Bown et al., 1993; Koimann et al., 1995; Moorhead and Evans, 1980; Pegelow et al., 1975) , suggesting that disruption of an 11q gene may predispose to the development of neuroblastoma. Loss of heterozygosity (LOH) for 11q was detected in 5 ± 32% of primary neuroblastomas using restriction fragment length polymorphism markers (Fong et al., 1992; Srivatsan et al., 1993; Takeda et al., 1996; Takita et al., 1995) . Lastly, recent comparative genomic hybridization (CGH) studies have detected loss of 11q material in 10 ± 31% of neuroblastomas studied (Brinkschmidt et al., 1997; Lastowska et al., 1997; Plantaz et al., 1997; Van Gele et al., 1997; Vandesompele et al., 1998) . However, since each of the LOH and CGH studies were limited in size (17 ± 59 informative cases) and the sample populations were heterogeneous, the exact prevalence, cytogenetic location and clinical signi®cance of this somatically acquired chromosomal deletion has not been de®ned.
This study was therefore designed to determine the prevalence of 11q LOH in a large, representative panel of neuroblastomas. In addition, we sought to map the likely location of an 11q neuroblastoma suppressor gene, and to determine the clinical signi®cance of 11q LOH in neuroblastoma patients.
Results

Determination of the prevalence of 11q LOH in primary neuroblastomas
In order to have a representative patient cohort, we ®rst identi®ed 295 patients from the Children's Cancer Group (CCG) with both diagnostic tumor and constitutional DNAs available for analysis. All patients were registered on the most recent Phase III CCG clinical trials and the cohort was chosen to represent the known distribution of clinical (age at diagnosis, stage, histopathology) and biological (MYCN ampli®cation, 1p LOH) variables typically observed at diagnosis (Brodeur and Castleberry, 1997) (Table 1) .
All samples were ®rst screened for LOH with a panel of nine highly informative microsatellite markers that were evenly distributed along 11q (11.1 cM average density) (Yuan et al., 1997) . Thereafter, 11q allelic data for individual specimens were obtained from closely linked markers at loci with constitutional homozygosity and/or informative breakpoints (Table 2 ). LOH at multiple 11q loci (median number loci/case with LOH=6; range 3 ± 15) was detected in 129/295 (44%) primary neuroblastomas. Representative data for four primary tumor and constitutional DNA pairs are shown in Figure 1 . We used a strict de®nition for assigning LOH (60% reduction in allelic intensity) and there were many samples with`allelic imbalance' (reduction in intensity of 40 ± 59%) which were scored as no LOH and are not considered further.
Deletion mapping
Eighty-two of the 129 primary neuroblastomas (64%) with 11q LOH had evidence for allelic deletion at all marker loci assayed (Figure 2 , mean number of informative loci assayed for each tumor=8.7; range 4 ± 24). The remaining 47 tumor specimens with partial 11q LOH were further analysed to map the smallest region of overlap (SRO) of all deletions. Only one tumor (CCG137) was shown to have two separate regions of LOH. Thirty-seven tumors had large, terminal regions of LOH with varying breakpoints within 11q12 ± 21. LOH, with retention of heterozygosity at telomeric loci, was observed in 12 cases. All 129 tumors with 11q LOH had allelic loss between the microsatellite loci D11S1998 and D11S4464 (11q23). Higher resolution deletion mapping with additional markers in select tumors with interstitial deletions de®ned a SRO within 11q23.3 marked proximally by D11S1340 and distally by D11S1299 (2.1 cM of genetic distance, Figure 2 ). Frozen tumor material was available from case CCG137 for dual-colored interphase FISH. The majority of nuclei showed one signal at 11q23.3 (MLL probe) in contrast to two centromeric signals (Figure 3) , which served to con®rm and re®ne the centromeric boundary of the SRO. 
Familial neuroblastomas
Fifteen neuroblastomas from patients with a family history of the disease were assayed for 11q allelic status with six microsatellite markers spanning 11q13 ± 23 (Table 3) . Five tumors (33%) showed LOH, and in each case there was LOH at all informative microsatellite markers assayed (n=28 informative loci). We Figure 1 Representative LOH data from four primary tumor (T) and constitutional (C) DNA pairs at microsatellite loci within chromosome bands 11q13, 11q14, 11q21 ± 22 and 11q23. Arrowheads indicate the allele that was deleted in the tumor specimen for each microsatellite marker scored as having LOH were unable to con®rm an interstitial 11q13 deletion that was detected by CGH in one case with no 11q LOH (Altura et al., 1997) . The ®ve cases with 11q LOH were of various clinical stages, but none were MYCN ampli®ed (no MYCN data available on two stage 1 tumors). Since these specimens were ascertained for linkage studies, parental blood was available. At each microsatellite locus informative for such analyses, the deleted allele was of maternal origin (n=22).
11q allelic status in neuroblastoma cell lines
Allelic status for 11q was analysed in 21 neuroblastoma cell lines (16 with MYCN ampli®cation; 18 with 1p36 deletion/rearrangement) at 11 microsatellite markers (Table 4) . Allelic status could be scored directly when constitutional DNA specimens were available (n=7). None of these seven neuroblastoma cell lines had LOH at any 11q polymorphic loci (6/7 had MYCN ampli®cation and 7/7 had 1p deletion). Allelic status could be inferred by analysis of cell line genotypes at multiple loci in the remaining cell lines, with homozygosity at contiguous markers suggesting hemizygous deletion. Although the probability of constitutional homozygosity at contiguous, multiallelic loci is small (0.0001 for markers D11S2000 ± D11S4464), we performed dual-colored FISH to con®rm 11q allelic status. The ®ve cell lines homozygous throughout the 11q22 ± 23 region were proven to have 11q deletions by dierential FISH hybridization of probes to the MLL gene (11q23.3, closely linked to marker D11S1356) and to the chromosome 11 centromeric region. The KAN cell line, which was heterozygous at D11S4464 but homozygous at the remaining 11q22 ± 23 loci, had two signals for both the MLL and centromeric loci (Figure 3) . Thus, by combining the PCR and FISH data we conclude that 5/21 (24%) neuroblastoma cell lines had an 11q deletion. All deletions were large, with the most distal breakpoint mapping within 11q22 (D11S898). There was a trend towards an inverse relationship between MYCN ampli®cation and 11q allelic status. Of the 16 cell lines with MYCN ampli®cation, only three were shown to have an 11q deletion. In contrast, 3/5 of the MYCN single copy cell lines had 11q deletions (P=0.075).
Clinical correlations
There was no signi®cant association between 11q LOH status and patient age at diagnosis, disease stage or tumor histopathologic grade (Table 1) . However, there was a strong inverse relationship between 11q allelic status and MYCN ampli®cation (P50.001). MYCN ampli®cation was identi®ed in only 10 of 129 primary neuroblastomas with chromosome 11q LOH (27.4 expected). When the Expanded view of a segment of the 11q23 genetic map containing markers used to de®ne SRO with centiMorgan (cM) distance from 11pter indicated. The MLL gene is tightly linked to the D11S1356 microsatellite locus. Deletion mapping data for the two cases that de®ne a 2.1 cM SRO, marked proximally by D11S1340 (CCG137) and distally by D11S1299 (CCG009), are shown. For tumor CCG137, D11S1356 was not informative by PCR, but the tightly linked MLL locus was deleted by FISH. Representative LOH data that de®ne the SRO are shown at right with arrowheads indicating the deleted allele at all microsatellite markers with LOH Frequent 11q LOH in neuroblastoma C Guo et al 230 cases with unampli®ed MYCN were analysed separately, 11q LOH was signi®cantly correlated with advanced stage disease (P=0.008) and unfavorable Shimada histopathology (P=0.042). Lastly, there was a trend towards an inverse relationship between 11q LOH and 1p36 LOH in the entire patient cohort (P=0.073), but not in the MYCN single copy subset of cases (P=0.291).
A total of 237 patients were fully evaluable for disease outcome, and these patients had the same distribution of clinical and biological variables as the entire 295 patient cohort (e.g. 48% Stage 4, 24% MYCN ampli®ed, 46% with 11q LOH). There was no dierence in event-free or overall survival probability for patients strati®ed by 11q LOH status. The 3-year overall survival (OS) probability was 74% for those Figure 4) . Nonetheless, analysis of 11q LOH did not provide additional prognostic information when entered into a Cox multivariate analysis after age at diagnosis, disease stage and MYCN ampli®cation status (Table 5) .
Discussion
This study provides the ®rst comprehensive evaluation of 11q allelic status in human neuroblastomas. The long arm of chromosome 11 is deleted in many human cancers (Nowak and Shows, 1995) and recently has been recognized as a target for nonrandom deletions in neuroblastoma. A review of the cytogenetic literature reported a 15 ± 20% prevalence of 11q deletions in neuroblastomas, but successful karyotyping is often restricted to the more malignant subset of tumors (many with MYCN ampli®cation) and tumor-derived cell lines (Mertens et al., 1997) . The LOH and CGH studies reported to date showed a 5 ± 32% prevalence of 11q deletions, but were limited to relatively small and heterogeneous patient populations (Brinkschmidt et al., 1997; Fong et al., 1992; Lastowska et al., 1997; Plantaz et al., 1997; Srivatsan et al., 1993; Takeda et al., 1996; Takita et al., 1995; Van Gele et al., 1997; Vandesompele et al., 1998) . Thus, although the long arm of chromosome 11 has been postulated to harbor a neuroblastoma suppressor gene, no study had ®rmly established the frequency of allelic deletion in a representative series of cases or had clearly de®ned a SRO. We found that 44% of primary neuroblastomas had clear evidence for 11q23 LOH, suggesting that it is the most frequent target of allelic deletion currently identi®ed in primary neuroblastomas. Chromosome band 1p36 LOH occurs in 30 ± 35% of primary neuroblastomas in unselected series (Caron et al., 1996b; Gehring et al., 1995; Martinsson et al., 1995; White et al., 1995) . Other regions of the genome, such as 3p, 4p, 9p, 14q and 18q, may also be subject to allelic deletion in up to one-third of specimens (Caron et al., 1996a; Fong et al., 1992; Hallstensson et al., 1997; Takita et al., 1997) . The primary neuroblastomas used in this study were obtained at initial diagnosis from patients strictly representative of the known natural distribution of clinical and biological prognostic variables (Table 1) . Therefore, the 44% prevalence of 11q LOH detected here should be an Figure 4 Kaplan-Meier overall probability of survival curves for 237 patients strati®ed by status of 11q LOH and MYCN ampli®cation. Number of patients in each stratum are indicated in parentheses. Among the 180 patients whose tumors had a single copy of MYCN, the 3-year overall survival probability was 91% for those with no 11q LOH versus 75% for those with 11q LOH Frequent 11q LOH in neuroblastoma C Guo et al accurate estimate of the overall frequency of 11q LOH in any large, unselected series of neuroblastomas. Our data is consistent with a common region of LOH mapping within chromosome subband 11q23.3. Review of the 59 published cases of sporadic neuroblastoma with 11q deletion detected by RFLP or CGH analysis (Brinkschmidt et al., 1997; Lastowska et al., 1997; Plantaz et al., 1997; Srivatsan et al., 1993; Takeda et al., 1996; Van Gele et al., 1997; Vandesompele et al., 1998) indicate that there is a common region of deletion from 11q14 ± q24 (data not shown). Our data con®rm the observations by CGH that most 11q deletions are large and interstitial deletions rare. By including a large number of samples in our study, we were able to identify a sucient number of tumors with informative deletion breakpoints to re®ne the location of a commonly deleted genomic region. Higher resolution mapping in these tumors identi®ed a 2.1 cM region within 11q23.3 that was deleted in all tumors with 11q LOH. This SRO, which is approximately 3.0 megabases in physical distance (http://www.sanger.ac.uk), includes the MLL gene locus at its centromeric boundary and is telomeric to both the ATM and PPP2R1B tumor suppressor gene loci (Schuler et al., 1996) . Thus, we have identi®ed a genomic region that is small enough to allow for the identi®cation and analysis of positional candidate neuroblastoma suppressor genes.
We included 15 familial neuroblastomas in this study and found 11q LOH in 5/15. This is consistent with previous observations that molecular genetic alterations in hereditary cases are similar to thoses observed in sporadic tumors . In each case and at all loci evaluated, the deleted microsatellite allele was inherited from the patient's mother. Interestingly, the SRO de®ned in this study is close to (but does not overlap) a familial paraganglioma locus (PGLI). The PGLI gene has not yet been identi®ed but is considered to be subjected to genomic imprinting as familial paragangliomas are inherited in an autosomal dominant manner exclusively through paternal transmission (Baysal et al., 1997) . If our preliminary observation of preferential maternal 11q homolog loss is con®rmed in a larger series of sporadic cases, and because imprinted genes often occur in clusters, it would suggest that an 11q23 neuroblastoma suppressor gene is subject to epigenetic modi®cation.
Deletions of 11q were less frequently observed in tumor-derived neuroblastoma cell lines than primary tumors. This may re¯ect the fact that cell line establishment is generally restricted to tumors with a highly malignant phenotype. In our series of neuroblastoma cell lines, 71% had MYCN ampli®cation and 81% had a 1p deletion, consistent with previous reports (Biedler et al., 1980; Brodeur et al., 1977 Brodeur et al., , 1981 . This is in contrast to the primary tumors in this study, which had a 21% and 32% prevalence of MYCN ampli®cation and 1p LOH, respectively. We used a combination of genotyping at highly informative polymorphic microsatellite loci and dual-colored FISH to establish 11q allelic status in the neuroblastoma cell lines. All deletions appeared to be large, but two 11q-deleted cell lines showed heterozygosity at D11S898, con®rming results of a recent CGH study (Van Gele et al., 1997) . Thus, the cell line data lend further support to the existence of a common region of deletion distal to 11q22. Lastly, these data help explain previous observations that transfer of an intact human chromosome 11 into the neuroblastoma cell line NGP induced early stages of dierentiation (Bader et al., 1991) .
As originally proposed by there appear to be three distinct biological types of neuroblastoma. At the benign end of the spectrum are hyperdiploid tumors that typically occur in infants with localized disease. In contrast, neuroblastomas with MYCN ampli®cation are highly malignant and generally occur in patients over one year of age with widely disseminated disease. Our data indicate that 11q LOH may be a genetic marker for an intermediate group of tumors. The majority of tumors with 11q LOH did not have MYCN ampli®cation, had an unfavorable histopathologic grade, and were from patients with advanced disease stage. It is therefore not surprising that within the MYCN single copy subset, 11q LOH was associated with decreased survival probability in univariate analysis. However, in multivariate analysis, 11q LOH status did not add prognostic information to the information currently available from age at diagnosis, disease stage and MYCN ampli®cation status, thus limiting the clinical utility of this genetic variable.
In conclusion, we have identi®ed chromosome sub-band 11q23.3 as a common site of allelic deletion in primary neuroblastomas. Our data support the hypothesis that a tumor suppressor gene located within 11q23.3 is inactivated during the malignant evolution of a large subset of primary neuroblastomas. In contrast to 1p LOH, 11q allelic deletion is inversely correlated with MYCN amplification. Therefore, we speculate that 11q LOH may help de®ne a genetically distinct subset of neuroblastomas with an intermediate clinical phenotype. Eorts to identify a putative 11q23.3 neuroblastoma suppressor gene will rely upon further re®nement of the SRO and characterization of candidate transcripts within this region.
Materials and methods
Specimens
Two hundred and ninety-®ve paired tissue samples were obtained from the CCG Neuroblastoma Reference Bank as part of CCG biology study B974. All patients were diagnosed between March 1985 and December 1996 and registered on the most recent CCG Phase III trials. Disease stage was assigned according to Evans et al. (1971) and histopathologic grade assigned according to Shimada et al. (1984) . The only criteria for inclusion in this study was the availability of at least 100 mg of snap-frozen histologically con®rmed neuroblastoma obtained at initial diagnosis and the availability of a matched, ®coll-separated mononuclear cell pellet from blood or bone marrow that was free of tumor by immunohistochemistry (Moss et al., 1991) . In addition, 15 familial neuroblastomas with matched constitutional DNA samples , and 21 primary neuroblastomaderived cell line DNAs (seven with matched constitutional DNA), were included in this study but were excluded from the clinical correlative analyses. DNA was prepared by anion-exchange chromatography (Qiagen, Valencia, CA, USA).
Polymorphic Markers
A panel of 24 microsatellite markers spanning 11q were used to screen for LOH in this study (Table 2) . These 24 markers span 88.6 cM of DNA and were ordered according to the Marsh®eld Chromosome 11 Sex-Average Linkage map (http://www.marshmed.org). Additional markers were used as necessary for deletion mapping to ®ll gaps and placed on the Marsh®eld map (marker data available upon request). Other available genetic, radiation hybrid and physical maps were used to con®rm the Marsh®eld order assignment, and any marker with discordant mapping information was excluded.
Specimen genotyping and 11q LOH determination
PCR ampli®cation was performed in 20 ml volumes with 40 ng of human genomic DNA as a template. Each reaction contained 0.2 mM of each primer, 0.2 mM of each dNTP, 1.5 mM MgCl 2, 16PCR buer and 1 U of AmpliTaq Gold DNA polymerase (Perkin Elmer Cetus, Branchburg, NJ, USA). The sense primer was end-labeled with g 733 P-dATP using T4 polynucleotide kinase (Promega, Madison, WI, USA) prior to PCR. Ampli®cation was performed with a touchdown procedure consisting of an initial 12 min denaturation at 958C; 15 cycles of 45 s denaturation at 958C and an annealing/extension temperature starting at 708C for 1 min and decreasing by 0.78C each cycle; 15 ± 25 cycles of 958C for 45 s, 55 ± 608C for 30 s and 728C for 1 min; and a 7 min ®nal extension at 728C. Radiolabeled PCR products were separated in an 8% polyacrylamide/7M urea sequencing gel and autoradiographed at room temperature for 2 ± 12 h. LOH was determined visually by two independent investigators and con®rmed by densitometric analysis (NIH Image software package v1.55) when results were equivocal according to the formula:
Area normal allele 1aArea normal allele 2 Area tumor allele 1aArea tumor allele 2 with LOH being assigned by a score of 40.4 (at least a 60% reduction in allelic intensity). All breakpoint-de®ning LOH assignments were con®rmed by repeat genotyping.
Fluorescence in situ hybridization
Detection of 11q23.3 allelic status was con®rmed in selected neuroblastoma cases by dual-colored interphase FISH. Touch preparations were made on glass slides from frozen primary tumor or cell culture pellet. Digoxigenin-labeled MLL (Oncor, Gaithersburg, MD, USA) and SpectrumGreenlabeled CEP11 (Vysis, Downers Grove, IL, USA) were used to detect 11q23.3 and chromosome 11 centromeric DNA copy number, respectively, according to the manufacturer's recommendations and as previously described (Maris et al., 1996; White et al., 1995) . A minimum of 100 nuclei were counted for each experiment.
MYCN ampli®cation and chromosome 1p36 LOH
From 1986 ± 1993 MYCN ampli®cation was determined by Southern hybridization (Brodeur et al., 1984) . After 1993, it was determined by MYCN protein expression as measured by semi-quantitative PCR and immunoperoxidase staining (Seeger et al., 1988) . Chromosome band 1p36 allelic status was determined by analysis of polymorphic markers D1S243, D1S468, D1S2145, D1S1646 and D1S214 as described previously .
Statistical analyses
Clinical and biological features were compared by the exact conditional chi-square test, survival analyses performed by the method of Kaplan and Meier (1958) , and multivariate analyses performed by the Cox proportional hazards method (Cox, 1972) .
